Hetty Carraway
@carrawayhetty.bsky.social
Director of Leukemia Program, Vice Chair of Strategy and Enterprise Development at Taussig Cancer Institute @ClevelandClinic Tweets are Mine 🏀
Reposted by Hetty Carraway
Reposted by Hetty Carraway
Evolution of MDS Management Hinges on Standardized Disease Classification, Molecularly Informed Risk Stratification
@carrawayhetty.bsky.social @clevelandclinic.bsky.social #MDS #mdssm
www.onclive.com/view/evoluti...
@carrawayhetty.bsky.social @clevelandclinic.bsky.social #MDS #mdssm
www.onclive.com/view/evoluti...
Evolution of MDS Management Hinges on Standardized Disease Classification, Molecularly Informed Risk Stratification
Hetty E. Carraway, MD, MBA, highlights the evolving molecular classification of MDS and novel agents in the therapeutic arsenal.
www.onclive.com
July 22, 2025 at 9:01 PM
Evolution of MDS Management Hinges on Standardized Disease Classification, Molecularly Informed Risk Stratification
@carrawayhetty.bsky.social @clevelandclinic.bsky.social #MDS #mdssm
www.onclive.com/view/evoluti...
@carrawayhetty.bsky.social @clevelandclinic.bsky.social #MDS #mdssm
www.onclive.com/view/evoluti...
Reposted by Hetty Carraway
What a fantastic night for dreams coming true! Can't wait to watch all of their journeys continue!
April 15, 2025 at 2:06 AM
What a fantastic night for dreams coming true! Can't wait to watch all of their journeys continue!
Reposted by Hetty Carraway
More researchers are now eligible for the ASH Bridge Grant!
With NIH funding cuts disrupting study sections, ASH expanded eligibility for midcareer investigators.
Learn how ASH is taking action to support hematology researchers: https://bit.ly/4hW5arC
#ASHAwards #Fight4Hematology #HemeSky
With NIH funding cuts disrupting study sections, ASH expanded eligibility for midcareer investigators.
Learn how ASH is taking action to support hematology researchers: https://bit.ly/4hW5arC
#ASHAwards #Fight4Hematology #HemeSky
Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards
The American Society of Hematology (ASH) was already looking to expand its Bridge Grant program when changes to the National Institutes of Health (NIH) funding landscape created greater urgency.
bit.ly
April 4, 2025 at 1:00 PM
More researchers are now eligible for the ASH Bridge Grant!
With NIH funding cuts disrupting study sections, ASH expanded eligibility for midcareer investigators.
Learn how ASH is taking action to support hematology researchers: https://bit.ly/4hW5arC
#ASHAwards #Fight4Hematology #HemeSky
With NIH funding cuts disrupting study sections, ASH expanded eligibility for midcareer investigators.
Learn how ASH is taking action to support hematology researchers: https://bit.ly/4hW5arC
#ASHAwards #Fight4Hematology #HemeSky
Reposted by Hetty Carraway
Cutting HHS staff to “save money” is like firing all the firefighters to lower the city’s water bill - it makes no damn sense
Staff are less than 1% of the HHS budget - but they’re the ones who respond when there’s a fire
They’re not saving money. They’re letting it (our health) all burn
🚒💨 🔥🏥🔥
Staff are less than 1% of the HHS budget - but they’re the ones who respond when there’s a fire
They’re not saving money. They’re letting it (our health) all burn
🚒💨 🔥🏥🔥
HHS doctors, scientists and tobacco control staff, rare disease experts, cancer drug wizards -- all fired today or leaving in recent weeks.
Yet.
🚨 At HHS, staff make up less than one percent of the overall agency budget. 🚨
www.nytimes.com/2025/04/01/h...
Yet.
🚨 At HHS, staff make up less than one percent of the overall agency budget. 🚨
www.nytimes.com/2025/04/01/h...
Federal Health Workers Make Up Less Than 1% of Agency Spending (Gift Article)
Health Secretary Robert F. Kennedy Jr. suggests that laying off thousands of federal workers would tame a massive budget. But nearly all of the agency’s money goes to hospitals, doctors and nursing ho...
www.nytimes.com
April 1, 2025 at 6:26 PM
Cutting HHS staff to “save money” is like firing all the firefighters to lower the city’s water bill - it makes no damn sense
Staff are less than 1% of the HHS budget - but they’re the ones who respond when there’s a fire
They’re not saving money. They’re letting it (our health) all burn
🚒💨 🔥🏥🔥
Staff are less than 1% of the HHS budget - but they’re the ones who respond when there’s a fire
They’re not saving money. They’re letting it (our health) all burn
🚒💨 🔥🏥🔥
Reposted by Hetty Carraway
Paige Bueckers has set a new UConn WBB record for points in an NCAA Tournament game in today's win over Oklahoma 🔥
◽ 40 PTS
◽ 16/27 FG
◽ 6/8 3-PT FG
◽ 40 PTS
◽ 16/27 FG
◽ 6/8 3-PT FG
March 29, 2025 at 11:39 PM
Paige Bueckers has set a new UConn WBB record for points in an NCAA Tournament game in today's win over Oklahoma 🔥
◽ 40 PTS
◽ 16/27 FG
◽ 6/8 3-PT FG
◽ 40 PTS
◽ 16/27 FG
◽ 6/8 3-PT FG
Reposted by Hetty Carraway
A review on the role of #MDM2 in regulating the #ImmuneMicroenvironment, tumor #ImmuneEvasion, & hyperprogression during #immunotherapy, with insights on the application of MDM2 inhibitors in combination with immunotherapy in tumors with MDM2 overexpression. #medsky
www.sciencedirect.co...
www.sciencedirect.co...
March 31, 2025 at 11:30 PM
A review on the role of #MDM2 in regulating the #ImmuneMicroenvironment, tumor #ImmuneEvasion, & hyperprogression during #immunotherapy, with insights on the application of MDM2 inhibitors in combination with immunotherapy in tumors with MDM2 overexpression. #medsky
www.sciencedirect.co...
www.sciencedirect.co...
Reposted by Hetty Carraway
My first @bloodjournal.bsky.social article!
Very helpful @bloodjournal.bsky.social review by @akritigjain.bsky.social & Aaron Gerds on anemia in myelofibrosis!
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
January 19, 2025 at 11:28 PM
My first @bloodjournal.bsky.social article!
Reposted by Hetty Carraway
Happy to share our work published in Nature Medicine!
We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...
We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...
T cell malignancies after CAR T cell therapy in the DESCAR-T registry - Nature Medicine
This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France between 2018 and 2024 shows th...
www.nature.com
January 8, 2025 at 2:23 PM
Happy to share our work published in Nature Medicine!
We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...
We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...
Reposted by Hetty Carraway
How I Do It: Interpreting Clinical Trial Results
An excellent rubric for understanding and interpreting randomized clinical trials in #journal_CHESTCritCare: hubs.la/Q030pjgL0
#JournalCHEST
An excellent rubric for understanding and interpreting randomized clinical trials in #journal_CHESTCritCare: hubs.la/Q030pjgL0
#JournalCHEST
December 30, 2024 at 12:20 PM
How I Do It: Interpreting Clinical Trial Results
An excellent rubric for understanding and interpreting randomized clinical trials in #journal_CHESTCritCare: hubs.la/Q030pjgL0
#JournalCHEST
An excellent rubric for understanding and interpreting randomized clinical trials in #journal_CHESTCritCare: hubs.la/Q030pjgL0
#JournalCHEST
Reposted by Hetty Carraway
10 Questions With Kaitlyn Dykes, chair of #ASHTrainee Council
📰In this ASH News Daily article, Dr. Dykes is asked "Who's your ASH-lebrity/the ASH luminary you most admire?"
Read more for the answer. And tell us: who's your ASH-lebrity? https://bit.ly/3ZIzD5G #ASH24
#HemeSky #Hematology
📰In this ASH News Daily article, Dr. Dykes is asked "Who's your ASH-lebrity/the ASH luminary you most admire?"
Read more for the answer. And tell us: who's your ASH-lebrity? https://bit.ly/3ZIzD5G #ASH24
#HemeSky #Hematology
January 1, 2025 at 4:56 PM
10 Questions With Kaitlyn Dykes, chair of #ASHTrainee Council
📰In this ASH News Daily article, Dr. Dykes is asked "Who's your ASH-lebrity/the ASH luminary you most admire?"
Read more for the answer. And tell us: who's your ASH-lebrity? https://bit.ly/3ZIzD5G #ASH24
#HemeSky #Hematology
📰In this ASH News Daily article, Dr. Dykes is asked "Who's your ASH-lebrity/the ASH luminary you most admire?"
Read more for the answer. And tell us: who's your ASH-lebrity? https://bit.ly/3ZIzD5G #ASH24
#HemeSky #Hematology
Reposted by Hetty Carraway
Cancer prevention is one of the most critical challenges of our time - Karen Knudsen
@drkarenknudsen.bsky.social
oncodaily.com/blog/215298
#Medicine #Health #Oncology #OncoDaily #Cancer
@drkarenknudsen.bsky.social
oncodaily.com/blog/215298
#Medicine #Health #Oncology #OncoDaily #Cancer
Karen Knudsen: Cancer prevention is one of the most critical challenges of our time - OncoDaily
Karen Knudsen: Cancer prevention is one of the most critical challenges of our time / Abu Dhabi, Altagracia Gomez, Arthur C. Brooks, Bojan Obradović, cancer,
oncodaily.com
January 1, 2025 at 5:17 PM
Cancer prevention is one of the most critical challenges of our time - Karen Knudsen
@drkarenknudsen.bsky.social
oncodaily.com/blog/215298
#Medicine #Health #Oncology #OncoDaily #Cancer
@drkarenknudsen.bsky.social
oncodaily.com/blog/215298
#Medicine #Health #Oncology #OncoDaily #Cancer
Reposted by Hetty Carraway
My New Year’s resolution is to berate myself less for things I wish I could have done better, to learn from my mistakes, and give myself more credit for the things I did well but promptly forgot/ignored because academics love to live from crisis to crisis
January 1, 2025 at 4:38 AM
My New Year’s resolution is to berate myself less for things I wish I could have done better, to learn from my mistakes, and give myself more credit for the things I did well but promptly forgot/ignored because academics love to live from crisis to crisis
Reposted by Hetty Carraway
Our assessment of a person's epigenetic ("biological") age has been centered on DNA methylation. A new report shows that a set of 7 histone markers has comparable accuracy and also uncovers new pathways of aging biology
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
January 1, 2025 at 8:36 PM
Our assessment of a person's epigenetic ("biological") age has been centered on DNA methylation. A new report shows that a set of 7 histone markers has comparable accuracy and also uncovers new pathways of aging biology
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Reposted by Hetty Carraway
Most previous epigenetic age predictors were focused on DNA methylation. Our own model suggested nucleosome positioning as an age predictor a year ago onlinelibrary.wiley.com/doi/full/10....
Aging clock based on nucleosome reorganisation derived from cell‐free DNA
We show that aging is associated with an increase in the distance between nucleosomes, which can be used to predict a person's age and conduct age classification. We developed the first aging clock b...
onlinelibrary.wiley.com
January 1, 2025 at 8:50 PM
Most previous epigenetic age predictors were focused on DNA methylation. Our own model suggested nucleosome positioning as an age predictor a year ago onlinelibrary.wiley.com/doi/full/10....
Reposted by Hetty Carraway
Bioart, courtesy of the NIH. All images are in the public domain and available for download as high-quality SVGs.
bioart.niaid.nih.gov
bioart.niaid.nih.gov
December 17, 2024 at 1:15 AM
Bioart, courtesy of the NIH. All images are in the public domain and available for download as high-quality SVGs.
bioart.niaid.nih.gov
bioart.niaid.nih.gov
Reposted by Hetty Carraway
As an oncologist, I get constant reminders that holidays are joyful & meaningful milestones, but not every yr & not for everyone. If you are with #grief, I hope this will remind you that you belong to something vast & are not alone.
#MedSky #OncSky #LongCovid
www.nytimes.com/2024/12/20/s...
#MedSky #OncSky #LongCovid
www.nytimes.com/2024/12/20/s...
Grief Makes Us Time Travelers (Gift Article)
A neuroscientist studying memory, I used to believe time was linear. Then my mother had a stroke.
www.nytimes.com
December 20, 2024 at 5:08 PM
As an oncologist, I get constant reminders that holidays are joyful & meaningful milestones, but not every yr & not for everyone. If you are with #grief, I hope this will remind you that you belong to something vast & are not alone.
#MedSky #OncSky #LongCovid
www.nytimes.com/2024/12/20/s...
#MedSky #OncSky #LongCovid
www.nytimes.com/2024/12/20/s...
Reposted by Hetty Carraway
The most complete collection of uniformly processed ChIP-seq data on identification of transcription factor binding sites for human and mouse. Convenient web interface with advanced search, browsing and genome browser based on the BioUML platform. gtrd.biouml.org/
December 20, 2024 at 6:00 PM
The most complete collection of uniformly processed ChIP-seq data on identification of transcription factor binding sites for human and mouse. Convenient web interface with advanced search, browsing and genome browser based on the BioUML platform. gtrd.biouml.org/
Reposted by Hetty Carraway
💡 Why mentor with ASH?
• Inspire future hematologists
• Foster career growth
• Address workforce shortages
Apply by January 9: https://bit.ly/3VLCPwb
#ASHTrainee #Hematology #Mentor #HemeSky #Bloodsky 🩸
• Inspire future hematologists
• Foster career growth
• Address workforce shortages
Apply by January 9: https://bit.ly/3VLCPwb
#ASHTrainee #Hematology #Mentor #HemeSky #Bloodsky 🩸
December 20, 2024 at 6:33 PM
💡 Why mentor with ASH?
• Inspire future hematologists
• Foster career growth
• Address workforce shortages
Apply by January 9: https://bit.ly/3VLCPwb
#ASHTrainee #Hematology #Mentor #HemeSky #Bloodsky 🩸
• Inspire future hematologists
• Foster career growth
• Address workforce shortages
Apply by January 9: https://bit.ly/3VLCPwb
#ASHTrainee #Hematology #Mentor #HemeSky #Bloodsky 🩸
Reposted by Hetty Carraway
Although still in 'First Edition' style, I am happy to finally share our latest article on DNMT3A double mutant AML. Hope to be able to share the way-easier-to-read print version of the paper soon! (1/2) #hemesky ashpublications.org/bloodadvance...
Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis
Key Points. 1. Wildtype DNMT3A enhances TDG-mediated repair, whereas mutant DNMT3A impairs this process.2. Double mutant DNMT3A AML exhibits increased DNA
ashpublications.org
December 20, 2024 at 4:34 PM
Although still in 'First Edition' style, I am happy to finally share our latest article on DNMT3A double mutant AML. Hope to be able to share the way-easier-to-read print version of the paper soon! (1/2) #hemesky ashpublications.org/bloodadvance...
Reposted by Hetty Carraway
The FDA has approved BRAFTOVI in combination with cetuximab and mFOLFOX6 for first-line treatment in patients with metastatic colorectal cancer with a BRAF V600E mutation. The approval is based on the BREAKWATER study, for which MD Anderson’s Dr. Scott Kopetz is co-PI. 1/2
FDA grants accelerated approval
The Food and Drug Administration granted accelerated approval to encorafenib.
www.fda.gov
December 21, 2024 at 2:28 AM
The FDA has approved BRAFTOVI in combination with cetuximab and mFOLFOX6 for first-line treatment in patients with metastatic colorectal cancer with a BRAF V600E mutation. The approval is based on the BREAKWATER study, for which MD Anderson’s Dr. Scott Kopetz is co-PI. 1/2
Reposted by Hetty Carraway
🩸Erythropoiesis
#medsky #IMsky #internalmedicine #hemesky #hematology #heme #physiology #manualofmedicine
#medsky #IMsky #internalmedicine #hemesky #hematology #heme #physiology #manualofmedicine
December 11, 2024 at 11:29 AM
🩸Erythropoiesis
#medsky #IMsky #internalmedicine #hemesky #hematology #heme #physiology #manualofmedicine
#medsky #IMsky #internalmedicine #hemesky #hematology #heme #physiology #manualofmedicine
Reposted by Hetty Carraway
🩸Hematopoietic stem cell differentiation with cytokine regulation #hemesky #hemeonc #medsky #IMsky #internalmedicine #hemepath #pathsky #stemcells
December 14, 2024 at 1:00 PM
🩸Hematopoietic stem cell differentiation with cytokine regulation #hemesky #hemeonc #medsky #IMsky #internalmedicine #hemepath #pathsky #stemcells
Reposted by Hetty Carraway
💊 Chemotherapy: disrupting cancer cell cell growth and survival at multiple levels.
This handy diagram summarizes chemotherapy classes and where they fit according to their mechanism of action ⚙️
#oncsky #hemeonc #hemesky #pharmsky #medsky #IMsky #cancer #chemo
(Falzone et al., 2023. Cell)
This handy diagram summarizes chemotherapy classes and where they fit according to their mechanism of action ⚙️
#oncsky #hemeonc #hemesky #pharmsky #medsky #IMsky #cancer #chemo
(Falzone et al., 2023. Cell)
December 15, 2024 at 1:29 PM